1 results found.

Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Sta Clinical Trial using MOR00208; lenalidomide; Correlative Studies

Ohio State University Comprehensive Cancer Center - Recruiting 18 years to 80 years.
- A Phase II Study of MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia(CLL)/Small Lymphocytic Lymphoma (SLL)Prolymphocytic Leukemia (PLL) or Patients With Untreated CLL/SLL/PLL.
MOR00208; lenalidomide; Correlative Studies